Keros Therapeutics’ ambitions to go up against Merck & Co’s Winrevair with its investigational pulmonary arterial hypertension therapy, cibotercept, have taken a knock after safety concerns halted enrolment in two treatment arms of its Phase II trial. The move was triggered by unexpected cases of pericardial effusion with the drug at its higher doses, prompting a 73% decline in its share price on NASDAQ on 12 December, and leaving it trading at around cash at $18.43.
Key Takeaways
An unexpected safety concern has halted two arms of a Phase II study of Keros's pulmonary arterial hypertension drug candidate.
Some hope remains but the setback means it will be harder for cibotercept to rival Merck & Co's similar therapy, Winrevair.
A recent deal with Takeda means that Keros does have a good cash position.
Keros’s path forward is far from clear, but some analysts say that there is still some hope for the product...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
